May 17th 2024
Artificial intelligence use in prostate cancer encompasses 4 main areas including diagnostic imaging, prediction of outcomes, histopathology, and treatment planning.
Medical Crossfire®: Expert Exchanges to Maximize Clinical Outcomes for Patients with CRPC Through Evidence-Based Personalized Therapy
View More
Everything You Need to Know About PARP Inhibitor Combinations in Prostate Cancer Care: Why? For Whom? And When?
View More
Advances In™: Targeting PSMA to Advance Diagnosis And Management Of Patients With Prostate Cancer
View More
Clinical Case Vignette Series: Integrating Recent Data into Practice to Improve Outcomes in Advanced Prostate Cancer
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?
View More
Medical Crossfire®: Where Are We in the World of ADCs? From HER2 to CEACAM5, TROP2, HER3, CDH6, B7H3, c-MET and Beyond!
View More
Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer
View More
Active Surveillance for Prostate Cancer: How to Do It Right
May 16th 2017In this review of active surveillance for favorable-risk prostate cancer, we will discuss the rationality of this approach, the biological evidence for employing active surveillance in Gleason pattern 3 and 4 prostate cancer, patient selection for active surveillance, clinical trial data on active surveillance, and the role of prostate cancer biomarkers and imaging studies for clinical decision making in patients with low-risk disease.
Tailored Prostate Cancer Screening May Be Warranted for Black Men
April 27th 2017The higher prostate cancer death rates seen among black men in the United States may be due to a higher incidence of preclinical disease and higher risk of metastatic progression, suggesting that different screening policies could benefit this population.
Sexual and urinary morbidities resulting from treatment of pelvic malignancies are common. Awareness of these complications is critical in order to properly counsel patients regarding potential side effects and to facilitate prompt diagnosis and management.
Genomic Decipher Score Predicts Prostate Cancer Metastasis, Mortality
February 17th 2017The Decipher prostate cancer gene-expression classifier can predict patients’ risk of metastasis and prostate cancer-specific mortality using biopsy specimens prior to radical prostatectomy or radiotherapy plus androgen deprivation.
Liquid Biopsy Shows Promise in Advanced Prostate Cancer
February 13th 2017“Liquid biopsy” analyses of circulating tumor DNA from blood samples potentially reveal prognostic information about metastatic castration-resistant prostate cancer, and might point the way for development of new targeted treatments.
Antiandrogen With Salvage RT Can Prolong Survival in Prostate Cancer
February 8th 2017A long-term study found that adding 24 months of antiandrogen therapy with bicalutamide to salvage radiation therapy increased overall survival and prostate cancer–specific survival compared with placebo in men who underwent radical prostatectomy.
Radiolabeled Ligands Targeting PSMA May Benefit Men With Advanced Prostate Cancer
January 13th 2017A new German multicenter study is suggesting that lutetium-177 (Lu-177)-labeled PSMA-617 may be a promising new therapeutic agent for radioligand therapy in men with metastatic castration-resistant prostate cancer.
Prostate Cancer Outlook for 2017: The Search for Actionable Targets Continues
December 14th 2016Six therapies have demonstrated improved survival in metastatic castration-resistant prostate cancer, yet there is insufficient data regarding combination and sequencing of these agents, and predicting response or resistance to them. Prostate cancer patients, researchers, and clinicians alike await the results of key phase III studies in 2017 that could further impact how prostate cancer is managed.